Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1985 Nov;60(11):1025–1030. doi: 10.1136/adc.60.11.1025

Evaluation of oral and low dose intravenous prostaglandin E2 in management of ductus dependent congenital heart disease.

E D Silove, D G Roberts, J V de Giovanni
PMCID: PMC1777650  PMID: 3865636

Abstract

Prostaglandin E2 was given orally to 59 infants with ductus dependent congenital heart disease, and intravenous infusions were substituted for varying periods in 27 of them. An additional three neonates received intravenous treatment alone. Mean oral maintenance dose was 27 micrograms/kg per hour and the mean intravenous dose was 0.005 micrograms/kg per minute. Mean duration of treatment was 49 days (range 16 hours to 272 days). Oral treatment was almost always effective and was especially suitable for long term use. Low dose intravenous treatment was readily substituted when indicated. Complications were usually 'minor'. Growth of the infants and of their pulmonary arteries facilitated later surgical management.

Full text

PDF
1025

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bove E. L., Bull C., Stark J., de Leval M., Macartney F. J., Taylor J. F. Congenital heart disease in the neonate: results of surgical treatment. Arch Dis Child. 1983 Feb;58(2):137–141. doi: 10.1136/adc.58.2.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coe J. Y., Radley-Smith R., Yacoub M. Management of tricuspid atresia with orally administered prostaglandin E2. J Pediatr. 1982 Mar;100(3):496–497. doi: 10.1016/s0022-3476(82)80469-1. [DOI] [PubMed] [Google Scholar]
  3. Coe J. Y., Silove E. D. Oral prostaglandin E2 in pulmonary atresia. Lancet. 1979 Jun 16;1(8129):1297–1298. doi: 10.1016/s0140-6736(79)92259-1. [DOI] [PubMed] [Google Scholar]
  4. Cole R. B., Abman S., Aziz K. U., Bharati S., Lev M. Prolonged prostaglandin E1 infusion: histologic effects on the patent ductus arteriosus. Pediatrics. 1981 Jun;67(6):816–819. [PubMed] [Google Scholar]
  5. Cooke R. W., Meradji M., de Villeneuve V. H. Necrotising enterocolitis after cardiac catheterisation in infants. Arch Dis Child. 1980 Jan;55(1):66–68. doi: 10.1136/adc.55.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dickinson D. F., Arnold R., Wilkinson J. L. Outcome of treatment for neonates referred to a supraregional cardiac centre 1976-78. Arch Dis Child. 1982 May;57(5):328–333. doi: 10.1136/adc.57.5.328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dickinson D. F., Galloway R. W., Wilkinson J. L., Arnold R. Necrotising enterocolitis after neonatal cardiac catheterisation. Arch Dis Child. 1982 Jun;57(6):431–433. doi: 10.1136/adc.57.6.431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Freed M. D., Heymann M. A., Lewis A. B., Roehl S. L., Kensey R. C. Prostaglandin E1 infants with ductus arteriosus-dependent congenital heart disease. Circulation. 1981 Nov;64(5):899–905. doi: 10.1161/01.cir.64.5.899. [DOI] [PubMed] [Google Scholar]
  9. Gittenberger-de Groot A. C., Moulaert A. J., Harinck E., Becker A. E. Histopathology of the ductus arteriosus after prostaglandin E1 administration in ductus dependent cardiac anomalies. Br Heart J. 1978 Mar;40(3):215–220. doi: 10.1136/hrt.40.3.215. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hallidie-Smith K. A. Prostaglandin E1 in suspected ductus dependent cardiac malformation. Arch Dis Child. 1984 Nov;59(11):1020–1026. doi: 10.1136/adc.59.11.1020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Haworth S. G., Silove E. D. Pulmonary arterial structure in pulmonary atresia after prostaglandin E2 administration. Br Heart J. 1981 Mar;45(3):311–316. doi: 10.1136/hrt.45.3.311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lewis A. B., Freed M. D., Heymann M. A., Roehl S. L., Kensey R. C. Side effects of therapy with prostaglandin E1 in infants with critical congenital heart disease. Circulation. 1981 Nov;64(5):893–898. doi: 10.1161/01.cir.64.5.893. [DOI] [PubMed] [Google Scholar]
  13. MacMahon P., Gorham P. F., Arnold R., Wilkinson J. L., Hamilton D. I. Pulmonary artery growth during treatment with oral prostaglandin E2 in ductus dependent cyanotic congenital heart disease. Arch Dis Child. 1983 Mar;58(3):187–189. doi: 10.1136/adc.58.3.187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Olley P. M., Coceani F., Bodach E. E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation. 1976 Apr;53(4):728–731. doi: 10.1161/01.cir.53.4.728. [DOI] [PubMed] [Google Scholar]
  15. Park I. S., Nihill M. R., Titus J. L. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects. J Am Coll Cardiol. 1983 Feb;1(2 Pt 1):471–475. doi: 10.1016/s0735-1097(83)80075-8. [DOI] [PubMed] [Google Scholar]
  16. Silove E. D. Administration of E-type prostaglandins in ductus-dependent congenital heart disease. Pediatr Cardiol. 1982;2(4):303–305. doi: 10.1007/BF02426977. [DOI] [PubMed] [Google Scholar]
  17. Silove E. D., Coe J. Y., Shiu M. F., Brunt J. D., Page A. J., Singh S. P., Mitchell M. D. Oral prostaglandin E2 in ductus-dependent pulmonary circulation. Circulation. 1981 Mar;63(3):682–688. doi: 10.1161/01.cir.63.3.682. [DOI] [PubMed] [Google Scholar]
  18. Teixeira O. H., Carpenter B., MacMurray S. B., Vlad P. Long-term prostaglandin E1 therapy in congenital heart defects. J Am Coll Cardiol. 1984 Mar;3(3):838–843. doi: 10.1016/s0735-1097(84)80262-4. [DOI] [PubMed] [Google Scholar]
  19. Ueda K., Saito A., Nakano H., Aoshima M., Yokota M., Muraoka R., Iwaya T. Cortical hyperostosis following long-term administration of prostaglandin E1 in infants with cyanotic congenital heart disease. J Pediatr. 1980 Nov;97(5):834–836. doi: 10.1016/s0022-3476(80)80282-4. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES